Although long-term data in CD are available only for a few drugs, experience with the use of IL-23 inhibitors in dermatology, such as risankizumab and guselkumab for plaque psoriasis and psoriatic arthritis, demonstrates an excellent long-term safety profile with no obvious increase in infectious or neoplastic or cardiovascular risks [64,65]. This evidence concerns the gene IL23A and psoriasis vulgaris.